PittsburghV1, France, Analysis, bibRecord, 000585

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

Identifieur interne : 000585 ( France/Analysis ); précédent : 000584; suivant : 000586

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

Auteurs : Evan Y. Yu [États-Unis] ; Kurt Miller [Allemagne] ; Joel Nelson [États-Unis] ; Martin Gleave [Canada] ; Karim Fizazi [France] ; Judd W. Moul [États-Unis] ; Faith E. Nathan [États-Unis] ; Celestia S. Higano [États-Unis]

Source :

The Journal of urology [ 0022-5347 ] ; 2012.

RBID : Pascal:12-0248443

Descripteurs français

Pascal (Inist)
- Métastase, Diagnostic, Métastatique, Zibotentan, Stade avancé, Maladie, Chimiothérapie, Dépistage, Echec, Cancer de la prostate, Essai clinique phase III, Etude comparative, Tumeur de la prostate, Placebo, Homme, Castration, Résistance, Prostate, Prévention, Néphrologie, Urologie.
Wicri :
- topic : Maladie, Homme.

English descriptors

KwdEn :
- Advanced stage, Castration, Chemotherapy, Comparative study, Diagnosis, Disease, Failure, Human, Medical screening, Metastasis, Metastatic, Nephrology, Phase III trial, Placebo, Prevention, Prostate, Prostate cancer, Prostate tumor, Resistance, Urology, Zibotentan.

Abstract

Purpose: Understanding the extent of disease in asymptomatic patients with castration resistant prostate cancer is important when making treatment decisions and designing clinical trials. The ENTHUSE MO (ENdoTHelin A USE) trial (NCT00626548) was a large phase III study comparing the endothelin A receptor antagonist zibotentan with placebo in patients with nonmetastatic, castration resistant prostate cancer. The study was stopped prematurely after early efficacy review indicated that it was unlikely to meet its co-primary objectives of improved overall and progression-free survival vs placebo. Screening failed in an unexpectedly high number of patients. We investigated this screening failure rate to promote better classification of patients thought to have nonmetastatic castration resistant prostate cancer and inform the design of future clinical trials in this setting. Materials and Methods: The number of patients enrolled in and subsequently excluded from study was analyzed by geographic region and by the specialty of the investigating clinician (oncology or urology) who enrolled the study patients. Results: Of 2,577 patients enrolled in a total of 350 hospital based centers in 39 countries screening failed in 1,155 (45%). The most common reason for screening failure was the detection of metastatic disease in 32% of all screened patients and in 71% of those in whom screening failed. The leading reasons for failed screening did not differ between investigator specialties overall or by geographic region. Conclusions: The high frequency of asymptomatic metastasis in men thought to have nonmetastatic, castration resistant prostate cancer highlights the importance of periodic staging assessments for the condition. Optimal treatment modalities may differ for metastatic and nonmetastatic disease.

Affiliations:

Allemagne, Canada, France, États-Unis
Berlin, Caroline du Nord, Delaware, Pennsylvanie, Washington (État)
Berlin

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 003F94
to stream PascalFrancis, to step Curation: 000F22
to stream PascalFrancis, to step Checkpoint: 003903
to stream Main, to step Merge: 009B89
to stream Main, to step Curation: 009501
to stream Main, to step Exploration: 009501
to stream France, to step Extraction: 000585

Links to Exploration step

Pascal:12-0248443

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer</title>
<author><name sortKey="Yu, Evan Y" sort="Yu, Evan Y" uniqKey="Yu E" first="Evan Y." last="Yu">Evan Y. Yu</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Washington School of Medicine, Fred Hutchinson Cancer Research Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Charité Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nelson, Joel" sort="Nelson, Joel" uniqKey="Nelson J" first="Joel" last="Nelson">Joel Nelson</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gleave, Martin" sort="Gleave, Martin" uniqKey="Gleave M" first="Martin" last="Gleave">Martin Gleave</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut Gustave Roussy University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy University of Paris Sud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moul, Judd W" sort="Moul, Judd W" uniqKey="Moul J" first="Judd W." last="Moul">Judd W. Moul</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Division of Urology, Department of Surgery and Duke Prostate Center, Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nathan, Faith E" sort="Nathan, Faith E" uniqKey="Nathan F" first="Faith E." last="Nathan">Faith E. Nathan</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>AstraZeneca Pharmaceuticals L.P</s1>
<s2>Wilmington, Delaware</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Delaware</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S." last="Higano">Celestia S. Higano</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Washington School of Medicine, Fred Hutchinson Cancer Research Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0248443</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0248443 INIST</idno>
<idno type="RBID">Pascal:12-0248443</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003F94</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F22</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003903</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003903</idno>
<idno type="wicri:doubleKey">0022-5347:2012:Yu E:detection:of:previously</idno>
<idno type="wicri:Area/Main/Merge">009B89</idno>
<idno type="wicri:Area/Main/Curation">009501</idno>
<idno type="wicri:Area/Main/Exploration">009501</idno>
<idno type="wicri:Area/France/Extraction">000585</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer</title>
<author><name sortKey="Yu, Evan Y" sort="Yu, Evan Y" uniqKey="Yu E" first="Evan Y." last="Yu">Evan Y. Yu</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Washington School of Medicine, Fred Hutchinson Cancer Research Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Charité Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nelson, Joel" sort="Nelson, Joel" uniqKey="Nelson J" first="Joel" last="Nelson">Joel Nelson</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gleave, Martin" sort="Gleave, Martin" uniqKey="Gleave M" first="Martin" last="Gleave">Martin Gleave</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut Gustave Roussy University of Paris Sud</s1>
<s2>Villejuif</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy University of Paris Sud</wicri:noRegion>
<wicri:noRegion>Institut Gustave Roussy University of Paris Sud</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moul, Judd W" sort="Moul, Judd W" uniqKey="Moul J" first="Judd W." last="Moul">Judd W. Moul</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Division of Urology, Department of Surgery and Duke Prostate Center, Duke University Medical Center</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nathan, Faith E" sort="Nathan, Faith E" uniqKey="Nathan F" first="Faith E." last="Nathan">Faith E. Nathan</name>
<affiliation wicri:level="2"><inist:fA14 i1="07"><s1>AstraZeneca Pharmaceuticals L.P</s1>
<s2>Wilmington, Delaware</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Delaware</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S." last="Higano">Celestia S. Higano</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>University of Washington School of Medicine, Fred Hutchinson Cancer Research Center</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of urology</title>
<title level="j" type="abbreviated">J. urol.</title>
<idno type="ISSN">0022-5347</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of urology</title>
<title level="j" type="abbreviated">J. urol.</title>
<idno type="ISSN">0022-5347</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Castration</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Diagnosis</term>
<term>Disease</term>
<term>Failure</term>
<term>Human</term>
<term>Medical screening</term>
<term>Metastasis</term>
<term>Metastatic</term>
<term>Nephrology</term>
<term>Phase III trial</term>
<term>Placebo</term>
<term>Prevention</term>
<term>Prostate</term>
<term>Prostate cancer</term>
<term>Prostate tumor</term>
<term>Resistance</term>
<term>Urology</term>
<term>Zibotentan</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Métastase</term>
<term>Diagnostic</term>
<term>Métastatique</term>
<term>Zibotentan</term>
<term>Stade avancé</term>
<term>Maladie</term>
<term>Chimiothérapie</term>
<term>Dépistage</term>
<term>Echec</term>
<term>Cancer de la prostate</term>
<term>Essai clinique phase III</term>
<term>Etude comparative</term>
<term>Tumeur de la prostate</term>
<term>Placebo</term>
<term>Homme</term>
<term>Castration</term>
<term>Résistance</term>
<term>Prostate</term>
<term>Prévention</term>
<term>Néphrologie</term>
<term>Urologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Maladie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: Understanding the extent of disease in asymptomatic patients with castration resistant prostate cancer is important when making treatment decisions and designing clinical trials. The ENTHUSE MO (ENdoTHelin A USE) trial (NCT00626548) was a large phase III study comparing the endothelin A receptor antagonist zibotentan with placebo in patients with nonmetastatic, castration resistant prostate cancer. The study was stopped prematurely after early efficacy review indicated that it was unlikely to meet its co-primary objectives of improved overall and progression-free survival vs placebo. Screening failed in an unexpectedly high number of patients. We investigated this screening failure rate to promote better classification of patients thought to have nonmetastatic castration resistant prostate cancer and inform the design of future clinical trials in this setting. Materials and Methods: The number of patients enrolled in and subsequently excluded from study was analyzed by geographic region and by the specialty of the investigating clinician (oncology or urology) who enrolled the study patients. Results: Of 2,577 patients enrolled in a total of 350 hospital based centers in 39 countries screening failed in 1,155 (45%). The most common reason for screening failure was the detection of metastatic disease in 32% of all screened patients and in 71% of those in whom screening failed. The leading reasons for failed screening did not differ between investigator specialties overall or by geographic region. Conclusions: The high frequency of asymptomatic metastasis in men thought to have nonmetastatic, castration resistant prostate cancer highlights the importance of periodic staging assessments for the condition. Optimal treatment modalities may differ for metastatic and nonmetastatic disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Canada</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Berlin</li>
<li>Caroline du Nord</li>
<li>Delaware</li>
<li>Pennsylvanie</li>
<li>Washington (État)</li>
</region>
<settlement><li>Berlin</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Yu, Evan Y" sort="Yu, Evan Y" uniqKey="Yu E" first="Evan Y." last="Yu">Evan Y. Yu</name>
</region>
<name sortKey="Higano, Celestia S" sort="Higano, Celestia S" uniqKey="Higano C" first="Celestia S." last="Higano">Celestia S. Higano</name>
<name sortKey="Moul, Judd W" sort="Moul, Judd W" uniqKey="Moul J" first="Judd W." last="Moul">Judd W. Moul</name>
<name sortKey="Nathan, Faith E" sort="Nathan, Faith E" uniqKey="Nathan F" first="Faith E." last="Nathan">Faith E. Nathan</name>
<name sortKey="Nelson, Joel" sort="Nelson, Joel" uniqKey="Nelson J" first="Joel" last="Nelson">Joel Nelson</name>
</country>
<country name="Allemagne"><region name="Berlin"><name sortKey="Miller, Kurt" sort="Miller, Kurt" uniqKey="Miller K" first="Kurt" last="Miller">Kurt Miller</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Gleave, Martin" sort="Gleave, Martin" uniqKey="Gleave M" first="Martin" last="Gleave">Martin Gleave</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000585 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000585 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:12-0248443
   |texte=   Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri